首页> 外文会议>Conference on advancing manufacture of cell and gene therapies >MAINTAINING CD4/CD8 RATIO AND TH1-CTL SUBSETS OF CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS IN SERUM-FREE CULTURE CONDITIONS
【24h】

MAINTAINING CD4/CD8 RATIO AND TH1-CTL SUBSETS OF CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS IN SERUM-FREE CULTURE CONDITIONS

机译:在无血清培养条件下维持嵌合抗原受体(CAR)-T细胞的CD4 / CD8比率和TH1-CTL亚群

获取原文

摘要

Chimeric antigen receptor (CAR) T cells therapy is a promising strategy that significantly controlled the progress of cancer diseases. CAR-T cells could kill cancer cells through cellular immune response; therefore, CD8+ cytotoxic T cells are critical for CAR-T cell therapy. However, recent papers reported that CD4+ T helper cells were important for the response and maintenance of CAR-T cells in vivo. Here, we developed a serum-free CAR-T cell preparation process that maintained the T cell population and controlled the T cell subsets. The CD4+ and CD8+ T cell population in CAR-T cells were maintained at averagely 59.4 % and 34.6%, and the major T cell subsets were Th1 cells and cytotoxic T lymphocytes (CTLs), implying the potentially high cellular immune response. To verifying whether the prepared CAR-T cells were exhausted, the expression of several immune checkpoint markers was determined. Of interest, only less than 20% of CAR-T cells at endpoint were PD-1+ or CTLA4+, but more than 40% of CAR-T cells at the endpoint were TIM-3+, implying most CAR-T cells were not exhausted. These CAR-T cells produced more than 1 ng/mL of IFN-y in the response to the antigen. Altogether, CAR-T cells could be prepared in our serum-free process in the controlling of T cell subsets, leading to potential high therapeutic potency.
机译:嵌合抗原受体(CAR)T细胞疗法是一种有前途的策略,可以显着控制癌症疾病的进展。 CAR-T细胞可以通过细胞免疫反应杀死癌细胞。因此,CD8 +细胞毒性T细胞对于CAR-T细胞治疗至关重要。但是,最近的论文报道CD4 + T辅助细胞对于体内CAR-T细胞的应答和维持很重要。在这里,我们开发了一种无血清的CAR-T细胞制备过程,该过程可维持T细胞群体并控制T细胞亚群。 CAR-T细胞中的CD4 +和CD8 + T细胞平均维持在59.4%和34.6%,主要的T细胞亚群是Th1细胞和细胞毒性T淋巴细胞(CTL),这意味着潜在的高细胞免疫应答。为了验证制备的CAR-T细胞是否耗尽,确定了几种免疫检查点标记的表达。有趣的是,端点处只有不到20%的CAR-T细胞为PD-1 +或CTLA4 +,但端点处超过40%的CAR-T细胞为TIM-3 +,这意味着大多数CAR-T细胞并非累。这些CAR-T细胞对抗原的反应产生超过1 ng / mL的IFN-γ。总而言之,可以在我们的无血清过程中控制T细胞亚群来制备CAR-T细胞,从而带来潜在的高治疗效力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号